# Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease

> **NCT00134251** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals**

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** SLV308

## Key facts

- **NCT ID:** NCT00134251
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00134251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00134251, "Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00134251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*